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Abstract  1 
Near-infrared (NIR: 800 - 1,000 nm) fluorescent probes, which activate their 2 
fluorescence following interaction with functional biomolecules, are desirable for 3 
noninvasive and sensitive tumor diagnosis due to minimal tissue interference. Focusing 4 
on bioavailability and applicability, we developed a probe with a self-assembling 5 
polymer micelle, a lactosome, encapsulating various quantities of NIR dye (IC7-1). We 6 
also conjugated anti-HER2 single chain antibodies to the lactosome surface and 7 
examined the probe‟s capacity to detect HER2 in cells and in vivo. Micelles 8 
encapsulating 20 mol% IC7-1 (hIC7L) showed 30-fold higher fluorescence (em: 858 9 
nm) after micelle denaturation compared to aqueous buffer. Furthermore, antibody 10 
modification allowed specific activation of the probe (HER2-hIC7L) following 11 
internalization by HER2-positive cells, with the probe concentrating in lysosomes. 12 
HER2-hIC7L intravenously administered to mice clearly and specifically visualized 13 
HER2-positive tumors by in vivo optical imaging. These results indicate that 14 
HER2-hIC7L is a potential activatable NIR probe for sensitive tumor diagnosis. 15 
 16 
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Cancer is a major cause of death worldwide owing to vigorous cell growth, 2 
invasion, and critical metastasis induced by activation of a variety of biomolecules such 3 
as proteases 
1
 and growth factors 
2
. Therefore, the in vivo detection of such 4 
biomolecules, particularly in early disease stages, is important for effective treatment 5 
with molecular target drugs 
3
.  6 
 7 
Noninvasive molecular imaging techniques such as optical imaging, nuclear 8 
imaging, and magnetic resonance imaging are useful for disease detection 
4
. Among 9 
these, optical imaging techniques have been widely studied and have progressed in the 10 
past decade due to their technical convenience, lack of radiation exposure, high spatial 11 
and temporal resolutions, and availability of activatable fluorescence probes 
5
. To 12 
achieve highly sensitive noninvasive in vivo imaging with an optical imaging system, 13 
bioavailable fluorescence probes ideally would have excitation and emission 14 
wavelengths within near-infrared (NIR) region at the range of 800 - 1,000 nm, which 15 
minimizes signal attenuation and autofluorescence by tissues 
6
.    16 
In our previous study, we developed a nanocarrier-based NIR probe (IC7-1 17 
lactosome; IC7L, Fig. 1C) 
7
 composed of a cyanine dye „IC7-1‟ (Fig. 1A) and an 18 
5 
 
amphiphilic polydepsipeptide (Fig. 1B). As expected, IC7L showed suitable optical 1 
characteristics for in vivo imaging with excitation and emission wavelengths of 830 and 2 
858 nm, respectively 
7
, and could visualize tumors in vivo with less accumulation in the 3 
reticuloendothelial system (RES) 
7-9
. However, IC7L could not distinguish tumor 4 
properties such as expression of biomolecules related to malignancy since the tumor 5 
accumulation occurred via the enhanced permeability and retention (EPR) effect. 6 
To facilitate tumor biomolecule detection by IC7L, we sought to modify IC7L by 7 
two strategies: 1) attachment of a targeting ligand on the surface of IC7L, and 2) 8 
introduction of a signal activatable system that can suppress signals from non-targeted 9 
tissues (Fig. 1D). To make IC7L an activatable probe, we applied a self-quenching 10 
mechanism in which lipophilic dye is encapsulated at high concentrations in the 11 
hydrophobic core of the lactosome where it forms self-stacking structures that induce a 12 
quenched state. Using this strategy, we expected that the quenched probe would 13 
recognize the target-biomolecule, be delivered into the cell following biomolecule 14 
internalization, and then be dequenched to emit a fluorescence signal after probe 15 
denaturation or metabolism (Fig. 1E). As a target biomolecule, we chose human 16 
epidermal growth factor receptor 2 (HER2) due to its high expression in tumors, its 17 
close relationship with malignancy 
10
, and molecular its therapy applications 
11
. In 18 
6 
 
addition, since HER2 is internalized after interaction with antibodies and subsequently 1 
delivered to lysosomes for degradation 
12
, this process can be used to trigger probe 2 
dequenching to restore fluorescence emission. Thus, HER2 is a suitable target 3 
biomolecule for both probe evaluation and future therapeutic applications. 4 
 5 
In this study, we first prepared lactosomes encapsulating IC7-1 at a variety of 6 
concentrations, and evaluated both their quenching and dequenching properties in in 7 
vitro experiments. We found that lactosomes encapsulating 20 mol% IC7-1 functioned 8 
as activatable probes, and thus named this activatable probe hIC7L with “h” indicating a 9 
high dye concentration. We then conjugated an anti-HER2 single chain antibody on the 10 
hydrophilic surface of hIC7L to produce HER2-hIC7L, and evaluated its effectiveness 11 
as a targeting activatable NIR probe in vitro and in vivo. Since we also found that 12 
several other cyanine dyes could be used similarly to IC7-1 in this activatable system, 13 
we selected hCy5L (lactosome encapsulating 20 mol% Cy5) for microscopic study 14 






Preparation of IC7L 2 
All chemicals were commercially available and of the highest purity. The 3 
amphiphilic polymer of the lactosome (Fig. 1B, polysarcosine-block-poly-L-lactate 4 
(PSar70-block-PLLA30) with glycol capping at the N-terminal) was supplied by the 5 
Shimadzu Corporation (Kyoto, Japan). 6 
IC7L was prepared as previously described 
7
. In brief, PSar70-block-PLLA30 (388 7 
nmol) and IC7-1-PLLA30 (3.9 - 97 nmol) dissolved in chloroform (500 l) were dripped 8 
into a glass test tube. The solvent was removed under reduced pressure to form a thin 9 
film on the tube wall. Phosphate buffered saline (PBS, 0.1 M, pH 7.4) was then added to 10 
the test tube and heated at 82 ºC for 20 min. The resulting aqueous solution was filtered 11 
through a 0.20 m Acrodisc® syringe filter (Pall Corp, East Hills, NY). The IC7L size 12 
distribution was measured at 25 ºC using a Zetasizer Nano-S90 (Malvern Instruments 13 
Ltd., UK). 14 
IC7L (1 mg/ml, 100 l) with an IC7-1 concentration of 1-20 mol% was incubated 15 
in 100 l PBS (0.1 M, pH 7.4) with or without sodium dodecyl sulfate (SDS, 5% final 16 
concentration) for 30 min at room temperature. After incubation, 2.8 ml PBS was added 17 
to the solution and the fluorescence emission spectra were measured with a fluorescence 18 
8 
 
spectrometer (Fluorolog-3, HORIBA Jobin Yvon Inc., Kyoto, Japan) following 1 
excitation at 815 nm using a slit width of 5 nm for both excitation and emission 2 
measurements. The absorption spectra were measured using a UV-1800 (Shimadzu 3 
Corporation, Kyoto, Japan). 4 
 5 
Preparation of anti-HER2 single chain Fv anchored IC7L (HER2-IC7L) 6 
PSar56-block-PLLA30 without N-terminal capping was synthesized as we previously 7 
reported 
8
. N-terminal uncapped PSar56-block-PLLA30 (100 mg), N-succinimidyl 8 
3-maleimidopropionate (39.1 mg) and diisopropylethylamine (3.8 mg) were dissolved 9 
in 1.5 ml dry DMF and stirred for 7 hr at room temperature. The mixture was then 10 
purified on a size exclusion column (Sephadex LH-20, GE Healthcare, U.K.) using 11 
DMF as the eluent. The high molecular mass fraction was collected and dried in vacuo. 12 
Maleimide-PSar-block-PLLA (92mg, 90%); 
1
H NMR (DMSO-d6) δ7.01(d, 2H, J=11.6), 13 
5.19(t, 30H, J=7.0), 4.26-3.99(m, 150H), 2.91-2.72(m, 275H), 2.05(s, 3H), 1.46(d, 91H, 14 
J=6.8). 15 
The maleimide-PSar-block-PLLA (194 nmol), PSar70-block-PLLA30 (194 nmol), and 16 
IC7-1-PLLA30 (3.9 nmol for IC7L or 97 nmol for hIC7L) were used to prepare 17 




Anti-HER2 single chain Fv (scFv) (4D5 C10) with a cysteine at the C-terminus was a 2 
kind gift from CANON Inc. (Tokyo, Japan). Anti-HER2 scFv (300 g, 100 l PBS) was 3 
added to tris(2-carboxyethyl)phosphine hydrochloride (63.7 g) and incubated for 2 hr 4 
on ice before purification on a size-exclusion column (Sephadex G-50, GE Healthcare, 5 
UK) to obtain the reduced form of scFv. Anti-HER2 scFv was then added to 6 
maleimide-IC7L/hIC7L (1 mg/1 ml) and incubated for 4 hr on ice with protection from 7 
light. After incubation, cysteine·HCl (158 g) was added and further incubated for 30 8 
min on ice. The mixture was then ultracentrifuged in an Amicon
®
 ultra-4 Centrifugal 9 
Filter Unit (100 kDa-cutoff, Millipore, UK) to obtain HER2-IC7L/hIC7L. The purity 10 
was analyzed by size exclusion chromatography using a Superdex 200 10/300 GL 11 
column (GE Healthcare, U.K.) equilibrated with PBS at a flow rate of 0.5 ml/min. 12 
Absorbance at 215 and 830 nm was used to detect the lactosome and IC7-1, respectively, 13 
which confirmed that the absorbance peaks at both wavelengths were detected 14 
simultaneously in the high molecular weight fraction. The size distribution of 15 
HER2-IC7L was measured at 25 °C using a Zetasizer Nano-S90 and transmission 16 
electron microscopy that is described in detail in the supplementary material (Fig. S2). 17 
The concentration of anti-HER2 scFv conjugated to IC7L/hIC7L was measured by the 18 
10 
 
bicinchoninic acid (BCA) assay, and then the number (molar ratio) of the anti-HER2 1 
scFvs per lactosome was then calculated using the estimated molecular weight values: 2 
anti-HER2, scFv, 27 kDa; IC7L, 1,172 kDa; hIC7L, 1,315 kDa. The affinity of 3 
HER2-IC7L for HER2/neu was determined by surface plasmon resonance using the 4 
ProteOn XPR36 Protein Interaction Array system (BIO-RAD Laboratories, Osaka, 5 
Japan) 
13,14
 with recombinant human ErbB2/HER2 Fc chimera immobilized on the 6 
sensor chip. The sensorgrams of HER2-IC7L and IC7L were fitted by a bivalent 7 
interaction model to obtain dissociation rate constants. 8 
 9 
Cellular uptake study 10 
NCI-N87 human gastric cells (ATCC, Manassas, VA, USA) (HER2-expressing tumor 11 
cells) and SUIT-2 human pancreatic carcinoma cells (Health Science Research 12 
Resources Bank, Osaka, Japan) (HER2 low-expressing cells) were cultured in 13 
RPMI1640 with 10% fetal bovine serum at 37 °C in a humidified atmosphere 14 
containing 5% CO2 
15, 16
. After pre-incubation of cells (2 × 10
5
 cells) overnight in 24 15 
well poly-D-lysine-coated dishes (Biocoat, Becton Dickinson), probes (40 g/1 ml 16 
RPMI1640 with 50 M bovine serum albumin (BSA)) were added to the cells and 17 
incubated at 37 °C in a humidified atmosphere containing 5% CO2. At 1, 3 and 6 hr, 18 
11 
 
cells were washed twice with PBS and fluorescence images of the cells were acquired 1 
using a Clairvivo OPT (Shimadzu Corporation, Kyoto, Japan) with a 785 nm laser diode 2 
for excitation and a 845/55 nm bandpath filter for emission. After image acquisition, 3 
these cells were treated with 0.2 N NaOH and the cell lysate protein concentrations 4 
measured by BCA assay. The fluorescence intensity of the cells was analyzed by 5 
Clairvivo OPT display software ver. 2.60. The fluorescence intensity of the cells was 6 
represented as a ratio to the dosage as follows:  7 
protein)] (mg lysate [Cellcells]  the toadded probe  theofIntensity  nce[Fluoresce
cells]  theofIntensity  nce[Fluoresce
ratio FI

  8 
For the blocking study, NCI-N87 cells (2 × 10
5 
cells) were treated with trastuzumab 9 
(4.7 mg/1 ml RPMI1640 with 50 M BSA, 1000 mol-fold equivalent of HER2-IC7L) 10 
for 15 min and HER2-IC7L (40 g) was then added. Subsequent fluorescence 11 
measurements were carried out as described above.  12 
 13 
Preparation of Tumor-bearing mice 14 
Female nude mice (BALB/c nu/nu) supplied by Japan SLC, Inc. (Hamamatsu, Japan) 15 
were housed under a 12-h light/12-h dark cycle and given free access to food and water. 16 
The animal experiments performed in this study were conducted in accordance with 17 
institutional guidelines and approved by the Kyoto University Animal Care Committee, 18 
12 
 
Japan.  1 
NCI-N87 cells (5 × 10
6
 cells) suspended in 100 l PBS containing 50 % Geltrex 2 
(Invitrogen Japan, Tokyo, Japan) were subcutaneously inoculated into the right hind 3 
legs of mice (4 week old), and an in vivo imaging study was performed after a 4-week 4 
growth period. In addition, for evaluation of IC7L encapsulating 20 mol% IC7-1, 5 
SUIT-2 cells (5 × 10
6
 cells in 100 l PBS containing 50 % Geltrex) were also 6 
transplanted to the opposite side 2 weeks after the NCI-N87 transplantation.  7 
 8 
In vivo imaging study 9 
HER2-IC7L or IC7L (2 mg / ml PBS, 100 l) were injected into the tumor-bearing 10 
mice via the tail vein and NIR florescence images were taken using a Clairvivo OPT 11 
with a 785 nm laser diode for excitation, and a 845/55 nm bandpath filter for emission. 12 
During the imaging process, mice remained on the imaging stage under anesthesia using 13 
2.5% isoflurane gas in oxygen (1.5 l / min). Regions of interest (ROI) were designated 14 
for the tumor and background (around the neck) on the acquired images to measure 15 





Data are represented as the mean ± S.D. Statistical analyses were performed with 1 
two-way factorial ANOVA followed by a Tukey-Kramer test. Statistical analyses of the 2 
in vitro blocking study and in vivo study were performed with Bartlett's test followed by 3 
the Bonferroni-Holm method. A two-tailed value of p < 0.05 was considered to be 4 






Probe preparation and determination of optical properties 2 
The fluorescence and absorbance spectra of IC7L with encapsulated IC7-1 3 
concentrations varying from 1 to 20 mol% are shown in Fig. 2. The fluorescence of 4 
IC7L decreased in PBS with increasing IC7-1 concentrations used for lactosome 5 
preparation, and was similar to background levels when the IC7-1 concentration was 20 6 
mol% (Fig. 2A). On the other hand, the IC7L fluorescence intensity increased in SDS 7 
solution as the IC7-1 concentration increased (Fig. 2B). In fact, IC7L with 20 mol% 8 
IC7-1 produced 36.1 ± 5.5 fold higher fluorescence at 848 nm in SDS solution 9 
compared to PBS, while IC7L with 1 mol% IC7-1 showed similar fluorescence 10 
intensities in both SDS solution and PBS. The absorbance spectra showed a blue-shifted 11 
band around 750 nm that increased in intensity as the IC7-1 concentration increased in 12 
PBS (Fig. 2C) and decreased in SDS solution (Fig. 2D). Based on this result, for the 13 
following study we used IC7L with 1 mol% IC7-1 as an “always-on”-type probe and 14 
IC7L with 20 mol% IC7-1 as an “activatable” type probe referred to as “hIC7L”. In 15 
addition, as shown in the supplementary material, the lactosome probes encapsulating 16 
20 mol% of other cyanine dyes, including IR780 (em: 812 nm), IR797 (em: 828 nm), 17 
Cy5 (em: 671 nm) and ICG (em: 815 nm) also showed fluorescence activatable 18 
15 
 
properties that were similar to hIC7L (Fig.S1). 1 
For the HER2-IC7L/hIC7L preparation, the particle sizes of HER2-IC7L, 2 
HER2-hIC7L, IC7L and hIC7L were 31.0 ± 2.7 nm (n = 3), 30.0 ± 2.5 nm (n = 6), 30.4 3 
± 6.0 nm (n = 3) and 30.8 ± 4.7 nm (n = 6), respectively. The estimated average molar 4 
ratio of anti-HER2-scFvs conjugated to an IC7L or an hIC7L were 5.6 ± 1.8 (n = 3) and 5 
5.9 ± 0.9 (n = 6), respectively. The dissociation constant (Kd) of HER2-hIC7L against 6 
HER2 protein was about 0.014 ± 0.012 nM (n = 4). On the other hand, hIC7L did not 7 
bind to HER2 protein and a Kd value could not be calculated. 8 
 9 
In vitro study 10 
The uptake of probes by NCI-N87 cells (high expression levels of HER2) and 11 
SUIT-2 cells (low HER2 expression levels) was examined for 6 hr after administration 12 
(Fig. 3 and 4). With HER2-IC7L and IC7L sorted as the always-on probes (Fig. 3), the 13 
fluorescence of NCI-N87 cells at 1 hr after HER2-IC7L addition was significantly 14 
higher than that of cells treated with IC7L and eventually reached a plateau (Fig. 3A). 15 
With the activatable probes HER2-hIC7L and hIC7L (Fig. 4), HER2-hIC7L 16 
fluorescence in NCI-N87 cells increased gradually and was significantly higher than the 17 
hIC7L fluorescence in the cells 3 hr or more after addition (Fig. 4A). In contrast, probe 18 
16 
 
uptake by SUIT-2 cells (Fig. 3B and 4B) was consistently low for all four probes, and 1 
treatment with excess trastuzumab blocked uptake of HER2-hIC7L by NCI-N87 cells to  2 
levels that were similar to hIC7L uptake (Fig. 4C). Similar results were obtained with 3 
BT-474 and MCF-7 cells, which express high and low levels of HER2, respectively (Fig. 4 
S5). 5 
The intracellular probe localization was evaluated by fluorescence microscopy 6 
using HER2-hCy5L (Cy5 was encapsulated in lactosomes instead of IC7-1), which 7 
showed that the fluorescence localization was similar to the distribution of Lysotracker 8 
(Fig. S4).  9 
 10 
In vivo imaging study 11 
With the always-on probes, both HER2-IC7L and IC7L visualized NCI-N87 tumors 12 
in xenografted mice at 12 and 24 hr post-administration (Fig. 5A). However, there was 13 
no significant difference in the images and the calculated tumor-to-background (T/B) 14 
ratios between the HER2-IC7L- and IC7L-administered groups during the study 15 
duration (Fig. 5C, 1.8 ± 0.2 vs. 1.8 ± 0.1 at 12 hr and 2.0 ± 0.1 vs. 1.9 ± 0.1 at 24 hr). As 16 
for the activatable probes, HER2-hIC7L detected the NCI-N87 tumor more clearly at 12 17 
and 24 hr post-administration than did hIC7L (Fig. 5B). In addition, the T/B ratios of 18 
17 
 
HER2-hIC7L increased with time and provided higher values than those of hIC7L (Fig. 1 
5D, 2.4 ± 0.2 vs. 1.8 ± 0.2 at 12 hr and 2.8 ± 0.2 vs. 2.0 ± 0.3 at 24 hr). Meanwhile, the 2 
T/B ratios in the SUIT-2 tumors were unchanged regardless of the probe used (Fig. 5D, 3 
2.0 ± 0.2 vs. 2.0 ± 0.2 at 12 hr and 2.2 ± 0.1 vs. 2.2 ± 0.1 at 24 hr). In addition, similar 4 
in vivo fluorescence images were also obtained in BT-474 (HER2 high expressing cells) 5 




Discussion  1 
In this study, we first showed that the IC7L fluorescence was quenched with 2 
increasing concentrations of IC7-1 encapsulated in lactosomes (Fig. 2A). In the 3 
absorbance spectra, the peak around 750 nm emerged as the concentration of IC7-1 was 4 
higher in the aqueous buffer (Fig. 2C), and indicated the formation of H-dimers 
17
. 5 
Furthermore, in SDS solution, the quenched IC7L fluorescence was dequenched 6 
following lactosome degradation and subsequent release of the encapsulated dyes (Fig. 7 
2B).  Similar results were also obtained with lactosomes that encapsulated other 8 
cyanine dyes at a molar ratio of 20 mol% (Fig. S1). Therefore, this quenching would be 9 
attributable to the effective stacking of cyanine dye molecules within the hydrophobic 10 
core of the lactosome due to the probe‟s high lipophilicity, and these results indicate that 11 
lactosomes carrying 20 mol% of cyanine dyes can serve as activatable fluorescence 12 
probes.  13 
 14 
We then prepared HER2-hIC7L as a HER2-specific activatable NIR probe. The 15 
particle size of this probe was similar to hIC7L. Considering the smaller size of scFv (5 16 
nm)
18
 compared with the lactosome (30 nm), the occupied volume of anti-HER2-scFv 17 
in HER2-hIC7L was very low (presumed to be only about 2.7%). Therefore, the 18 
19 
 
conjugation of anti-HER2-scFv would have minimal effects on the structural properties 1 
of hIC7L. The fluorescence of HER2-hIC7L was recovered in HER2 high expressing 2 
cells but not in cells lacking HER2, and the increases in fluorescence ratios for HER2 3 
high expressing cells were much higher for HER2-hIC7L than HER2-IC7L. In addition, 4 
the fluorescence microscopy using HER2-hCy5L rather than HER2-hIC7L revealed that 5 
the HER2-hCy5L fluorescence was localized to the lysosomes 6 hours after treatment 6 
(Fig. S4). These in vitro studies thus verify the mechanism of fluorescence activation in 7 
anti-HER2 scFv-conjugated lactosomes encapsulating high concentrations of cyanine 8 
dyes in that: 1) they are targeted to HER2 expressed on the cell surface of tumors, 2) are 9 
internalized via interactions with HER2, and finally, 3) probe delivery to and 10 
denaturation in the lysosomes relieves quenching, leading to fluorescence recovery.  11 
 12 
Targeting ligands such as antibodies have been widely used in “active targeting 13 
systems” for tumor-specific imaging and drug delivery 19, 20. Therefore, we first 14 
performed an in vivo study using anti-HER2-scFv conjugated to the always-on type NIR 15 
lactosomes (HER2-IC7L) with the expectation that increased accumulation in tumors 16 
induced by active targeting of HER2 would be observed. Unfortunately, there was no 17 
difference in tumor fluorescence between HER2-IC7L and IC7L (Fig. 5A, C) and 18 
20 
 
anti-HER2 scFv could not provide beneficial effects for IC7L on HER2-expressing 1 
tumor accumulation. These results might be due to a fundamental feature of lactosomes 2 
in effective tumor delivery by an EPR effect 
8, 9
, as was also reported in previous works 3 
using other nanocarrier probes that showed similar diminished effectiveness of 4 
antibodies for tumor targeting 
21
.  5 
In contrast, compared to hIC7L, the activatable type HER2-hIC7L clearly 6 
visualized tumors expressing high levels of HER2 (Fig. 5B, D, S6). Since an antibody 7 
used as a targeting ligand was reportedly effective for increased cellular uptake of a 8 
nanocarrier probe in tumor tissue 
21
, anti-HER2 scFv would also likely accelerate the 9 
cellular uptake of HER2-hIC7L via interactions with HER2. This could lead to the 10 
dequenching of HER2-hIC7L inside tumor cells and provide clearer tumor images than 11 
hIC7L, while the total levels of HER2-hIC7L and hIC7L delivered in tumors might be 12 
similar with different rates of probe accumulation in intra- and extracellular spaces in 13 
tumors.  14 
In recent years, other groups also produced studies on micelle-based activatable 15 
probe 
22
 having fluorescence signals that were controlled by a self-quenching 16 
mechanism that was similar to our probe. While the probes from the previous studies 17 
could visualize tumors in vivo by the EPR effect, probe instability remained an unsolved 18 
21 
 
issue for in vivo imaging of functional molecules related to tumor malignancy (about 1 
60% of dyes were released at 24 hr after incubation in an aqueous solution). We thus 2 
employed a strategy wherein IC7-1 conjugated to the hydrophobic polymer of the 3 
lactosome (poly-L-lactic acid; PLLA) was encapsulated to form a stable complex in the 4 
lactosome core and suppressed release from the micelle 
7
. On this basis, we could 5 
achieve target-specifity in vivo tumor imaging.  6 
In this study we adopted HER2 as a target biomolecule because HER2 is a 7 
representative factor in molecular-targeted breast cancer therapy 
11
 and participates in 8 
the signal transmission of growth factors on the cell surface followed by internalization 9 
and eventual delivery to lysosomes for degradation 
23
.  These qualities make HER2 10 
suitable for evaluating fluorescence activation strategies using lactosome probes. 11 
However, this approach would not be limited to HER2, but could be applied to other 12 
biomolecular targets expressed on the tumor cell surface, such as membrane type 1 13 
matrix metalloproteinase 
24, 25
, folate receptors 
26
, epidermal growth factor receptors 
27
, 14 
and transferrin receptors 
28
. Therefore, these results would support that hIC7L coupled 15 
with antibodies targeting such biomolecules could be promising activatable NIR probes 16 
for specific visualization of target biomolecules expressed on tumors in vivo. Since 17 
optical imaging technologies have been rapidly advancing in terms of both probes and 18 
22 
 
modalities such as NIR endoscopic cameras 
5
 and clinical breast scanners 
29
 and is 1 
expected especially to provide an informative navigation aid for surgery 
30
, such 2 
activatable NIR probes would be clinically powerful tools for the diagnosis of cancer 3 
and other diseases. 4 
 5 
While HER2-hIC7L could visualize HER2-expressing tumors both in vitro and in 6 
vivo, significant background fluorescence was also seen in the images due to 7 
non-specific dequenching of hIC7L, which is in agreement with the observation that 8 
quenched hIC7L was gradually dequenched after 24-hour incubation in mice plasma at 9 
37 ºC (Fig. S3). In addition, nanocarriers with neutral or positive surface charges are 10 
known to cause non-specific cell internalization as was reported in in vitro studies 
31, 32
. 11 
Although the zeta potential of our lactosome probes was estimated to be -5.0 mV, this 12 
might not be sufficiently negative to avoid non-specific cellular uptake in tumors, 13 
especially during the delayed phase. Therefore, the improvement of in vivo stability and 14 
the introduction of negative charge on the probe surface should be considered in 15 
subsequent refinement of the probes to achieve higher contrast images.  16 
 17 
Compared with other in vivo imaging techniques, optical imaging can greatly 18 
23 
 
benefit from activatable probes. Although a variety of activatable optical probes have 1 
been developed 
5
, most have excitation and emission spectra in the visible region (400 - 2 
700 nm) and only a few lie in the NIR region (800 - 900 nm). For the two major 3 
strategies used to control probe fluorescence, photoinduced electron transfer (PeT) and 4 
Förster resonance energy transfer (FRET), there have been difficulties in developing 5 
NIR activatable probes, which for PeT may be due to the small charge separation 6 
between the highest occupied molecular orbital and the lowest unoccupied molecular 7 
orbital 
5, 33
, and for FRET because of the general lack of organic structures having 8 
absorption around 900 – 1,000 nm that is required for the regulation of 800 – 900 nm 9 
fluorescence 
34
. Inorganic fluorescence probes such as quantum dots 
35, 36
 and gold 10 
nanorods 
37
 have developed and shown promise in in vivo optical imaging; however, 11 
they still invoke concerns about heavy metal toxicity 
35
, though some trials have been 12 
performed that avoided this potential toxicity by coating onto the probe surface with 13 
biocompatible compounds such as polyethylene glycol 
38, 39
 and glutathione 
40
. In 14 
contrast, our probe is bioavailable since the lactosome is composed of the biodegradable 15 
materials poly-sarcosine and poly-L-lactic acid 
41, 42
, and, as with previous reports using 16 
lactosomes, showed no acute or transient toxicity in treated mice in all experiments 
7, 9
. 17 
Therefore, hIC7L conjugated with target-specific antibody derivatives appears to be a 18 
24 
 
safe, promising, and widely applicable probe for noninvasive in vivo diagnostic 1 
techniques used to detect target biomolecules. 2 
 3 
In conclusion, we developed HER2-hIC7L that shows self-quenched fluorescence 4 
and specifically interacts with HER2 expressed on tumor cells, followed by the 5 
internalization in these cells, whereupon the fluorescence is dequenched after micelle 6 
degradation. These results indicate that a targeting ligand such as an antibody- 7 
conjugated lactosome that encapsulates high concentrations of IC7-1 would be a useful 8 
NIR probe that is applicable for use in noninvasive in vivo optical imaging for specific 9 
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Figure Legends 1 
Figure 1. Schematic illustration of HER2-hIC7L design and strategy. A: IC7-1 chemical 2 
structure. B: Chemical structure of the amphiphilic block polymer of the “lactosome” 3 
(PSar-PLLA). C: Schematic illustration of our previously reported probe IC7L 4 
(always-on type probe) we previously reported 
7
. IC7L is a lactosome that encapsulates 5 
1 mol% IC7-1. D: Schematic illustration of the activatable type probe, HER2-hIC7L, 6 
developed in this study. The HER2-hIC7L is a lactosome encapsulating 20 mol% IC7-1 7 
with anti-HER2 scFv conjugated to the surface. HER2-hIC7L fluorescence is quenched 8 
due to self-quenching of IC7-1 in the hydrophobic core of the lactosome. E: Schematic 9 
explanation of the HER2-hIC7L fluorescence signal activation mechanism. Quenched 10 
HER2-hIC7L first interacts with HER2 expressed on the tumor, whereupon the probe is 11 
internalized, and then dequenched with subsequent probe denaturation. 12 
 13 
Figure 2. Optical characteristics of activatable type IC7L. Fluorescence emission (A, B) 14 
and absorbance spectra (C, D) of IC7L encapsulating IC7-1 molar ratios ranging from 1 15 
(purple), 2.5 (blue), 5 (green), 10 (orange) and 20 mol% (red) after incubation in PBS 16 




Figure 3. Cellular uptake of always-on type probes. NCI-N87 cells (A) or SUIT-2 cells 1 
(B) were treated with HER2-IC7L (bold line) or IC7L (dotted line). Fluorescence 2 
intensities were acquired for 6 hr. Data are expressed as the FI Ratio (mean ± S.D.) for 3 
3-4 samples. Comparison between the HER2-IC7L-treated and IC7L-treated groups was 4 
performed with two-way factorial ANOVA followed by a Tukey-Kramer test (*p < 0.05 5 
vs. IC7L).  6 
 7 
Figure 4. Cellular uptake of activatable-type probes. NCI-N87 cells (A) and SUIT-2 8 
cells (B) were treated with HER2-hIC7L (bold line) or hIC7L (dotted line), and the 9 
fluorescence intensities were acquired for 6 hr. For an inhibition study, NCI-N87 cells 10 
were pre-treated with 4.7 mg trastuzumab for 15 min and then treated with 11 
HER2-hIC7L for 6 hr (C). Data are expressed as the FI Ratio (mean ± S.D.) for 3-4 12 
samples. Comparisons between the HER2-hIC7L-treated and hIC7L-treated groups, and 13 
among each concentration of trastuzumab-pretreated HER2-hIC7L and hIC7L addition 14 
groups were performed with two-way factorial ANOVA followed by a Tukey-Kramer 15 
test (*p < 0.01 vs. hIC7L), and with Bartlett's test followed by the Bonferroni-Holm 16 




Figure 5. In vivo imaging studies. A: Fluorescence images of NCI-N87 cell xenografted 1 
mice at 0 (immediately after injection), 12, and 24 hr after administration of 2 
HER2-IC7L (upper) and IC7L (lower). The yellow arrows indicate the tumor. B: 3 
Fluorescence images of NCI-N87 (right hind leg) and SUIT-2 (left hind leg) cell 4 
xenografted mice at 0 (just after injection), 12, and 24 hr after administration of 5 
HER2-hIC7L (upper) and hIC7L (lower). The yellow and red arrows indicate the HER2 6 
high-expressing tumor (NCI-N87) and HER2 low-expressing tumor (SUIT-2), 7 
respectively. C,D: NCI-N87 and SUIT-2 tumor-to-background (T/B) fluorescence 8 
intensity ratio obtained from the region of interest of the tumor and background (around 9 
the neck) in mice administered with HER2-IC7L (red) and IC7L (blue) (C) or 10 
HER2-hIC7L (red) and hIC7L (blue) (D). Data are expressed as the T/B ratio (mean ± 11 
S.D.). Comparison of the each group was performed with Bartlett's test followed by the 12 
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